Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). J of Skin [Internet]. 2018 Dec. 17 [cited 2025 Apr. 19];2:S87. Available from: https://skin.dermsquared.com/skin/article/view/484